In a significant move, Lilly has allocated $1 billion towards a Boston-based biotech company focusing on developing a gene-editing cholesterol drug. Gene editing involves the modification of an organism’s DNA to achieve a desired trait, and in this case, it is being utilized to target cholesterol levels in the body. This substantial investment highlights the […]